130 related articles for article (PubMed ID: 38375741)
1. Prevalence and clinical profiles of anti-myelin-associated glycoprotein neuropathy in Japan: A nationwide survey study of 133 patients.
Aotsuka Y; Misawa S; Suichi T; Shibuya K; Nakamura K; Kano H; Otani R; Morooka M; Ogushi M; Nagashima K; Sato Y; Kuriyama N; Kuwabara S
Eur J Neurol; 2024 May; 31(5):e16249. PubMed ID: 38375741
[TBL] [Abstract][Full Text] [Related]
2. [Rapid improvement by rituximab treatment in a case of demyelinating polyneuropathy with anti-myelin-associated glycoprotein antibody].
Motoyama R; Yamakawa K; Suzuki S; Kusunoki S; Tanaka M
Rinsho Shinkeigaku; 2011 Oct; 51(10):761-4. PubMed ID: 22019868
[TBL] [Abstract][Full Text] [Related]
3. Long-term efficacy of rituximab in IgM anti-myelin-associated glycoprotein neuropathy: RIMAG follow-up study.
Iancu Ferfoglia R; Guimarães-Costa R; Viala K; Musset L; Neil J; Marin B; Léger JM
J Peripher Nerv Syst; 2016 Mar; 21(1):10-4. PubMed ID: 26748872
[TBL] [Abstract][Full Text] [Related]
4. Axonal loss influences the response to rituximab treatment in neuropathy associated with IgM monoclonal gammopathy with anti-myelin-associated glycoprotein antibody.
Kawagashira Y; Koike H; Ohyama K; Hashimoto R; Iijima M; Adachi H; Katsuno M; Chapman M; Lunn M; Sobue G
J Neurol Sci; 2015 Jan; 348(1-2):67-73. PubMed ID: 25467141
[TBL] [Abstract][Full Text] [Related]
5. Placebo-controlled trial of rituximab in IgM anti-myelin-associated glycoprotein neuropathy.
Léger JM; Viala K; Nicolas G; Créange A; Vallat JM; Pouget J; Clavelou P; Vial C; Steck A; Musset L; Marin B;
Neurology; 2013 Jun; 80(24):2217-25. PubMed ID: 23667063
[TBL] [Abstract][Full Text] [Related]
6. Chronic demyelinating neuropathy with anti-myelin-associated glycoprotein antibody without any detectable M-protein.
Sakamoto Y; Shimizu T; Tobisawa S; Isozaki E
Neurol Sci; 2017 Dec; 38(12):2165-2169. PubMed ID: 28980134
[TBL] [Abstract][Full Text] [Related]
7. [Anti-myelin-associated glycoprotein antibody positive IgM monoclonal gammopathy related peripheral neuropathy: 11 cases and literature review].
Gao XM; Jia MN; Qian M; Ren HT; Zhang L; Shen KN; Cao XX; Li J
Zhonghua Xue Ye Xue Za Zhi; 2019 Nov; 40(11):901-905. PubMed ID: 31856437
[No Abstract] [Full Text] [Related]
8. Anti-MAG antibodies in 202 patients: clinicopathological and therapeutic features.
Svahn J; Petiot P; Antoine JC; Vial C; Delmont E; Viala K; Steck AJ; Magot A; Cauquil C; Zarea A; Echaniz-Laguna A; Iancu Ferfoglia R; Gueguen A; Magy L; Léger JM; Kuntzer T; Ferraud K; Lacour A; Camdessanché JP;
J Neurol Neurosurg Psychiatry; 2018 May; 89(5):499-505. PubMed ID: 29070644
[TBL] [Abstract][Full Text] [Related]
9. Obinutuzumab, a new anti-CD20 antibody, and chlorambucil are active and effective in anti-myelin-associated glycoprotein antibody polyneuropathy.
Briani C; Visentin A; Salvalaggio A; Cacciavillani M; Trentin L
Eur J Neurol; 2019 Feb; 26(2):371-375. PubMed ID: 30315672
[TBL] [Abstract][Full Text] [Related]
10. Predictors of response to rituximab in patients with neuropathy and anti-myelin associated glycoprotein immunoglobulin M.
Benedetti L; Briani C; Grandis M; Vigo T; Gobbi M; Ghiglione E; Carpo M; Cocito D; Caporale CM; Sormani MP; Mancardi GL; Nobile-Orazio E; Schenone A
J Peripher Nerv Syst; 2007 Jun; 12(2):102-7. PubMed ID: 17565535
[TBL] [Abstract][Full Text] [Related]
11. Mutational Profile in 75 Patients With Anti-Myelin-Associated Glycoprotein Neuropathy: Clinical and Hematologic Therapy Response and Hints on New Therapeutic Targets.
Castellani F; Visentin A; Schirinzi E; Salvalaggio A; Cacciavillani M; Candiotto C; Baratè C; Cellini A; Bertorelle R; Siciliano G; Trentin L; Briani C
Neurol Neuroimmunol Neuroinflamm; 2023 Jul; 10(4):. PubMed ID: 37137530
[TBL] [Abstract][Full Text] [Related]
12. Anti-MAG associated cerebellar ataxia and response to rituximab.
Zis P; Rao DG; Hoggard N; Sarrigiannis PG; Hadjivassiliou M
J Neurol; 2018 Jan; 265(1):115-118. PubMed ID: 29159464
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapy for IgM anti-myelin-associated glycoprotein paraprotein-associated peripheral neuropathies.
Lunn MP; Nobile-Orazio E
Cochrane Database Syst Rev; 2016 Oct; 10(10):CD002827. PubMed ID: 27701752
[TBL] [Abstract][Full Text] [Related]
14. Prevalence, Clinical Profiles, and Prognosis of CIDP in Japanese Nationwide Survey: Analyses of 1,257 Diagnosis-Confirmed Patients.
Aotsuka Y; Misawa S; Suichi T; Shibuya K; Nakamura K; Kano H; Otani R; Morooka M; Ogushi M; Nagashima K; Sato Y; Kuriyama N; Kuwabara S
Neurology; 2024 Mar; 102(6):e209130. PubMed ID: 38408295
[TBL] [Abstract][Full Text] [Related]
15. Polyneuropathy with anti-sulfatide and anti-MAG antibodies: clinical, neurophysiological, pathological features and response to treatment.
Campagnolo M; Ferrari S; Dalla Torre C; Cabrini I; Cacciavillani M; Lucchetta M; Ruggero S; Toffanin E; Cavallaro T; Briani C
J Neuroimmunol; 2015 Apr; 281():1-4. PubMed ID: 25867460
[TBL] [Abstract][Full Text] [Related]
16. The BCL2 Inhibitor Venetoclax Plus Rituximab Is Active in MYD88 Wild-Type Polyneuropathy With Anti-MAG Antibodies.
Briani C; Visentin A; Castellani F; Cacciavillani M; Trentin L
Neurol Neuroimmunol Neuroinflamm; 2022 Jul; 9(4):. PubMed ID: 35798560
[TBL] [Abstract][Full Text] [Related]
17. The BCL2 Inhibitor Venetoclax Plus Rituximab Is Active in MYD88 Wild-Type Polyneuropathy With Anti-MAG Antibodies.
Briani C; Visentin A; Castellani F; Cacciavillani M; Trentin L
Neurol Neuroimmunol Neuroinflamm; 2022 Jul; 9(4):. PubMed ID: 35577568
[TBL] [Abstract][Full Text] [Related]
18. Anti-myelin-associated glycoprotein neuropathy: Where do we stand?
Stino AM; Elsheikh B; Allen JA
Muscle Nerve; 2023 Nov; 68(6):823-832. PubMed ID: 37602932
[TBL] [Abstract][Full Text] [Related]
19. IgM paraprotein and anti-MAG sensory polyneuropathy associated with Waldenstrom's macroglobulinaemia and medullary carcinoma of the thyroid.
Yang Y; Canepa C
BMJ Case Rep; 2021 Feb; 14(2):. PubMed ID: 33622752
[TBL] [Abstract][Full Text] [Related]
20. Acute neurological worsening after Rituximab treatment in patients with anti-MAG neuropathy.
Sala E; Robert-Varvat F; Paul S; Camdessanché JP; Antoine JC
J Neurol Sci; 2014 Oct; 345(1-2):224-7. PubMed ID: 25115501
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
